Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | COVID-19 vaccination in CLL

Mazyar Shadman • 25 May 2021
EHA 2021
Chronic Lymphocytic Leukemia Leukemia

Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, talks on COVID-19 vaccine recommendations for patients with chronic lymphocytic leukemia (CLL), highlighting potential efficacy limitations associated with disease biology. Dr Shadman also gives an overview of existing data on COVID-19 vaccine efficacy in patients with CLL and shares recommendations for vaccination. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Mazyar Shadman

1:17
Dose reductions to manage AEs of ibrutinib treatment for CLL
Mazyar Shadman • 10 Dec 2023
1:32
CD20-targeted CAR T-Cell therapy for patients with indolent B-cell NHL
Mazyar Shadman • 10 Dec 2023
1:06
Zanubrutinib in patients with B-cell malignancies who are acalabrutinib-intolerant
Mazyar Shadman • 10 Dec 2023
3:09
Retrospective analysis of clinical outcomes in pts with LBCL receiving CAR-T or autoSCT while in CR
Mazyar Shadman • 10 Dec 2023

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals